Lookup NU author(s): Professor Nicola Curtin,
Dr Andrew Hughes
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Pemetrexed disodium is a potent new antifolate which inhibits many folate-dependent reactions that are essential for cell proliferation. Its primary target is thymidylate synthase but it also inhibits folate-dependent enzymes involved in purine synthesis. Cells that are resistant to antifolates are generally less resistant to pemetrexed, irrespective of the mechanism of resistance. Pemetrexed has shown good activity in preclinical models with human tumour cells and xenografts. In the majority of clinical trials of pemetrexed, the dose-limiting toxic effect is neutropenia; other side-effects are mostly gastrointestinal. Preclinical studies indicate that the toxic effects of pemetrexed can be reduced by dietary folate, resulting in an improved therapeutic index. Low folate status is also associated with higher levels of toxicity in patients. As a single agent pemetrexed has shown good activity against non-small-cell lung cancer, squamous-cell carcinoma of head and neck, colon cancer, and breast cancer, and it appears to be particularly active in combination with cisplatin against non-small-cell lung cancer and mesothelioma. Phase II and III studies are underway. © 2001 Elsevier Science Ltd.
Author(s): Curtin, N.J., Hughes, A.N.
Publication type: Review
Publication status: Published
Journal: Lancet Oncology
Print publication date: 01/05/2001
ISSN (print): 1470-2045
ISSN (electronic): 1474-5488
PubMed id: 11905785